ketamine
Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)
Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.
dmt
Spotlight: Irvine Welsh: Reality Is Not Enough
"Irvine Welsh says psychedelic drug proves there is 'life before and after death'"
fda
Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression
"Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis."
cancer
Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)
"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."
cannabis
Spotlight: UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia (Aggarwal, et al, 2025)
"The study demonstrated improvements in subjective sleep quality and other captured PROMs in insomnia patients treated with cannabis-based medicinal products."
oral ketamine
Spotlight: A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Mus musculus) (Rocha, et al, 2025)
"No significant alterations were observed in liver and kidney function in either sex, nor in inflammation, apoptosis, or DNA damage in kidney tissues. Overall, these findings support the viability of voluntary oral ketamine administration and accentuate the need to refine the proposed model"
ketamine
Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)
"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
ketamine
Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative
"The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling adoption in hospital, outpatient, and home-care settings."
Spotlight: The State of Sexual Education: State Laws and Regulations Mandating Sexual Education in the United States (Nelson, et al, 2025)
"Although many states mandated sexual education, few required content beyond sexual abstinence, HIV, sexually transmitted infections, and child abuse prevention. Laws that make content optional or facilitate opt-outs can undermine access to this education."
ketamine
Spotlight: Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca2+-Permeable AMPA Receptors in Mice (Flowers, et al, 2025)
"Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the expression of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects."
Spotlight: Psychedelic Sensationalism: An Analysis of the Schedule Classification of Psilocybin (Wood, 2023)
"This paper asserts that drug regulation was used as a form of social control that aimed to stifle the progressive ideals of the youth counterculture movement and reinforce conservative American ideals."
Spotlight: [Exploring and treating complex trauma in everyday clinical reality in child and adolescent psychiatry] (Robin, 2025)
"This report highlights Ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles, where traditional treatments like electroconvulsive therapy often fail."
opioid use disorder
Spotlight: Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression (Manza, et al, 2025)
Ketamine was safe and generally well-tolerated. At 10-day follow-up post-ketamine infusions, participant acceptability ratings were mostly favorable. 3-month timepoint - strong treatment adherence with self-reported depression symptoms decrease
ketamine
Spotlight: Intravenous ketamine for suicide ideation in borderline personality and depression (Bachir, et al, 2025)
"This report highlights ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles where traditional treatments like electroconvulsive therapy often fail. "
recovery
Spotlight: Beyond Addiction Sept 19-22 2025
The First Online Conference Focused on
Psychedelic Treatments for Addiction and Long-term Recovery
Spotlight: Is there consciousness beyond the brain? (Goff, 2025)
More:
The Consciousness Issue: The Mystery of Being YouBig Think’s latest special issue journeys to the edges of science
psychedelic research
Spotlight: Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics? (Garcia-Romeu, 2025)
The relative contribution of drug vs. psychological support remains to be determined, though preliminary data indicate the therapeutic relationship can impact treatment outcomes [12], and factors such as environment, personality, and mindset can influence subjective drug effects.
